Is Buying 52-Week Stock Like LivaNova PLC (LIVN) a Winning Strategy?

June 14, 2018 - By Marie Mckinney

LivaNova PLC (NASDAQ:LIVN) Logo

The stock of LivaNova PLC (NASDAQ:LIVN) hit a new 52-week high and has $112.31 target or 7.00 % above today’s $104.96 share price. The 5 months bullish chart indicates low risk for the $5.08B company. The 1-year high was reported on Jun, 14 by Barchart.com. If the $112.31 price target is reached, the company will be worth $355.88 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 1.07% or $1.11 during the last trading session, reaching $104.96. About 395,958 shares traded. LivaNova PLC (NASDAQ:LIVN) has risen 41.94% since June 14, 2017 and is uptrending. It has outperformed by 29.37% the S&P500.

Analysts await LivaNova PLC (NASDAQ:LIVN) to report earnings on August, 8. They expect $0.84 EPS, down 16.83 % or $0.17 from last year’s $1.01 per share. LIVN’s profit will be $40.69M for 31.24 P/E if the $0.84 EPS becomes a reality. After $0.36 actual EPS reported by LivaNova PLC for the previous quarter, Wall Street now forecasts 133.33 % EPS growth.

More recent LivaNova PLC (NASDAQ:LIVN) news were published by: Streetinsider.com which released: “LivaNova plc (LIVN) Granted FDA Clearance & Completes First Implant for MEMO 4D Semi-Rigid Mitral Annuloplasty …” on June 14, 2018. Also Seekingalpha.com published the news titled: “Premarket analyst action – healthcare” on June 08, 2018. Benzinga.com‘s news article titled: “LivaNova Valuation Multiples Likely to Increase Amid Steady Progress, Stifel Says In Bullish Initiation” with publication date: June 08, 2018 was also an interesting one.

LivaNova PLC, a medical device company, designs, develops, makes, and sells therapeutic solutions worldwide. The company has market cap of $5.08 billion. It operates in three businesses: Neuromodulation, Cardiac Surgery, and Cardiac Rhythm Management. It currently has negative earnings. The Neuromodulation business designs, develops, and markets its Vagus Nerve Stimulation Therapy System, an implantable device to treat drug-resistant epilepsy and treatment-resistant depression (TRD).

LivaNova PLC (NASDAQ:LIVN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: